<DOC>
	<DOC>NCT00786422</DOC>
	<brief_summary>This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450 isoenzyme 3A4 (CYP 3A4) inducer for the entire 3-month study duration.</brief_summary>
	<brief_title>Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer</brief_title>
	<detailed_description>The following laboratory variables were determined at baseline at the local laboratories: Hemoglobin, platelets, activated partial thromboplastin time (aPTT), international normalized ratio (INR), alanine aminotransferase (ALT), and creatinine.</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
	<criteria>Confirmed acute symptomatic proximal deep vein thrombosis and/or pulmonary embolism Concomitant use of a strong CYP 3A4 inducer, (i.e., carbamazepine, phenytoin, rifampicin/rifampin, and rifabutin) Legal lower age limitations (country specific) Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of deep vein thrombosis and/or pulmonary embolism Other indication for vitamin K antagonist (VKA) than deep vein thrombosis and/or pulmonary embolism Concomitant use of strong CYP3A4 inhibitors (e.g., HIV protease inhibitors, systemic ketoconazole) Use of the strong CYP 3A4 inducers phenobarbital/primidone or St John's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Embolism and Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Embolism</keyword>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Enzyme Inducers</keyword>
	<keyword>CYP Inducers</keyword>
	<keyword>Cohort Study</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Human Immunodeficiency Virus (HIV)</keyword>
	<keyword>Neurologic disease</keyword>
	<keyword>Additional relevant MeSH terms:</keyword>
	<keyword>Fibrin Modulating Agents</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Cardiovascular Agents</keyword>
</DOC>